WO2009073820A2 - Conjugaison biopolymère-acide nucléique - Google Patents

Conjugaison biopolymère-acide nucléique Download PDF

Info

Publication number
WO2009073820A2
WO2009073820A2 PCT/US2008/085594 US2008085594W WO2009073820A2 WO 2009073820 A2 WO2009073820 A2 WO 2009073820A2 US 2008085594 W US2008085594 W US 2008085594W WO 2009073820 A2 WO2009073820 A2 WO 2009073820A2
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotide
solution
solvent
biopolymer
reaction mixture
Prior art date
Application number
PCT/US2008/085594
Other languages
English (en)
Other versions
WO2009073820A3 (fr
Inventor
Paul Hatala
Ryan Boomer
Markus Kurz
Original Assignee
Archemix Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp. filed Critical Archemix Corp.
Publication of WO2009073820A2 publication Critical patent/WO2009073820A2/fr
Publication of WO2009073820A3 publication Critical patent/WO2009073820A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Definitions

  • the invention relates to methods for the conjugation of a biopolymer, preferably a polyalkylene glycol (PAG), to an oligonucleotide wherein, in preferred embodiments, the oligonucleotide is an aptamer.
  • a biopolymer preferably a polyalkylene glycol (PAG)
  • PAG polyalkylene glycol
  • An aptamer is an isolated nucleic acid molecule that binds with high specificity and affinity to a target, such as a protein, small molecule, carbohydrate, peptide or any other biological molecule, through interactions other than Watson-Crick base pairing.
  • Aptamers are capable of specifically binding to selected targets and modulating the target's activity or binding interactions, e.g., through binding, aptamers may block or activate their target's ability to function. This functional property of specific binding to a target, is an inherent property.
  • aptamers have been generated for hundreds of proteins, including growth factors, transcription factors, enzymes, immunoglobulins and receptors.
  • a typical aptamer is 5-15 kDa in size (15-45 nucleotides), binds its target with nanomolar to sub- nanomolar affinity and discriminates against closely related targets (e.g., aptamers will typically not bind other proteins from the same gene family).
  • aptamers are capable of using the same types of binding interactions (e.g., hydrogen bonding, electrostatic complementarities, hydrophobic contacts, steric exclusion) that drive affinity and specificity in antibody-antigen complexes.
  • binding interactions e.g., hydrogen bonding, electrostatic complementarities, hydrophobic contacts, steric exclusion
  • Aptamers have a number of desirable characteristics for use as therapeutics and diagnostics including high specificity and affinity, biological efficacy and excellent pharmacokinetic properties.
  • Therapeutic compounds including therapeutic oligonucleotides often have short half-lives in the blood after injection into the body. Hence, it is often difficult to maintain a given therapeutic compound at a concentration, in the blood, sufficient to exert a desired physiological effect. This is because after therapeutic compounds are injected into a body these compounds are often rapidly cleared from the body due, for example, to: i) renal clearance and/or ii) uptake by macrophages in the liver and spleen.
  • sustained-release compositions and formulations are used to provide a means of controlling blood levels of the active ingredient. These composition and formulations also provide greater efficacy, safety, patient convenience and patient compliance.
  • the two most widely used approaches to obtain the sustained-action of a therapeutic compound include: 1) modifying the therapeutic compound to increase the circulating half- life (for example, by increasing the molecular weight of the therapeutic compound) and 2) encapsulating the therapeutic compound in, for example, polymer microspheres, liposomes or polymer micelles.
  • Biocompatible polymers that can be used for this purpose include, but are not limited to, polyalkylene glycols (PAGs), polylactide/glycolide polymers (PLGA), and polyaminoamine (PAMAM).
  • PAGs are especially well suited to conjugation with therapeutic compounds including oligonucleotides, preferably aptamers, and the use and safety of PAGS, in vivo, conjugated to therapeutic compounds including aptamers has been well documented.
  • proteins and oligonucleotides are often conjugated with polyethylene glycol (PEG), usually methoxy-PEG (mPEG), to achieve extended in vivo circulation as compared to unconjugated biopolymers.
  • PEG polyethylene glycol
  • mPEG methoxy-PEG
  • Polyethylene glycol exhibits a low interaction with the other bio-components owing to its steric repulsion effect and as a result, a therapeutic compound conjugated with polyethylene glycol often exhibits the desired functionality of decreased renal clearance, thereby, achieving a half-life in blood longer than that of the corresponding unconjugated therapeutic compound.
  • Figure 1 is a schematic representation of the in vitro aptamer selection (SELEXTM) process from pools of random sequence oligonucleotides.
  • Figure 2 illustrates various strategies for the synthesis of high molecular weight PEG-nucleic acid conjugates.
  • Figure 3 is a chromatographic trace of a 3'-5'-diPEGylated nucleic acid.
  • Figures 4 and 5 are HPLC traces of reaction mixtures 7 and 11 described in Example 1 , Table 1.
  • Figure 6 is an HPLC trace of starting material for PEGylation studies in Example 1.
  • Figure 7 shows a variable scheme for the PEGylation of an oligonucleotide.
  • Figure 8 is a series of HPLC traces that show the stability of an aptamer core at different time points under PEGylation conditions.
  • Figure 9 is an HPLC trace that illustrates the specificity of the PEGylation reaction using 2 equivalents of PEG reagent.
  • Figure 10 is an HPLC trace that illustrates the specificity of the PEGylation reaction using 3 equivalents of PEG reagent.
  • Figures 1 IA and 1 IB are a pair of LCMS graphs monitoring a PEGylation reaction.
  • Figure 12 is an HPLC trace showing co-injection of ARC1368-(CH 2 ) 6 NH2 (peak 2) and the all phosphate containing version of this oligonucleotide (peak 1).
  • the term "all phosphate containing version” or “all PO” refers to an oligonucleotide wherein the linker group between the sugar molecules is a phosphate group.
  • Figure 13 is an HPLC trace showing co-injection of ARC 1779 (peak 2) and the all phosphate containing version of this oligonucleotide (peak 1).
  • Figure 14 is a reverse-phase HPLC trace showing all ARC 1779 (peak 2) and the all phosphate containing version of this oligonucleotide (peak 1).
  • One aspect of the invention includes a method for attaching a polyalkylene glycol group to an oligonucleotide containing a terminal amine to form a polyalkene glycol- oligonucleotide derivative of formula I:
  • (I) wherein the method comprises: a) dissolving PAG-nitrophenylcarbonate in acetonitrile to form solution A; b) adding sodium bicarbonate buffer to an aqueous solution comprising the oligonucleotide to form solution B (wherein the pH of solution B is greater than or equal to 8.5); c) combining solution A and solution B to form the reaction mixture; and d) adding DMSO to the reaction mixture to form the final reaction mixture.
  • Another aspect of the invention includes a method for optimizing the yield of 1 :1 polyalkylene glycol-oligonucleotide in an aqueous solution comprising: a) dissolving PAG-nitrophenylcarbonate in acetonitrile to form solution A; b) adding sodium bicarbonate buffer to an aqueous solution comprising the oligonucleotide to form solution B (wherein the pH of solution B is greater than or equal to 8.5); c) combining solution A and solution B to form the reaction mixture; and d) adding DMSO to the reaction mixture to form the final reaction mixture.
  • Another aspect of the invention includes a method for attaching a polyalkylene glycol group to an oligonucleotide containing a primary amine to form 1 : 1 PAG-oligonucleotides comprising: a) dissolving PAG-nitrophenylcarbonate in acetonitrile to form solution A; b) adding sodium bicarbonate buffer to an aqueous solution comprising the oligonucleotide to form solution B (wherein the pH of solution B is greater than or equal to 8.5); c) combining solution A and solution B to form the reaction mixture; and d) adding DMSO to the reaction mixture to form the final reaction mixture.
  • Another aspect of the invention includes a method of reacting a PAG-nitrophenyl carbonate having the structure: with an oligonucleotide having the structure:
  • solution B (wherein the pH of solution B is greater than or equal to 8.5); c) combining solution A and solution B to form the reaction mixture; and d) adding DMSO to the reaction mixture to form the final reaction mixture.
  • Another aspect of the invention includes a method of reacting a PAG-nitrophenyl
  • the invention includes a method wherein said PAG- nitrophenylcarbonate is a mPEG-nitrophenylcarbonate.
  • the invention includes a method wherein the pH of the final reaction mixture is approximately 8.5.
  • the invention includes a method wherein the concentration of said oligonucleotide in said aqueous oligonucleotide solution is in a range between 30-70 mg/mL. In one aspect, the concentration of the oligonucleotide is 50 mg/mL.
  • the invention includes a method wherein the concentration of PAG-nitrophenylcarbonate in acetonitrile is in a range of about 175-225 mg/mL.
  • the invention includes a method wherein the volume of DMSO added is greater than the volume of solution A.
  • the invention includes a method wherein the oligonucleotide is an aptamer.
  • the invention includes a method wherein the percentage of DMSO in the final reaction mixture is less than 70% of the total volume of the final reaction mixture.
  • Another aspect of the invention includes a method of attaching a biopolymer to an oligonucleotide containing a terminal amine to form an oligonucleotide -biopolymer
  • the invention includes a method wherein the activated biopolymer is comprised of an activating group and a biopolymer, wherein said activating group is selected from the group consisting of nitrophenyl, N-hydroxysuccinimide (NHS), isocyanate, isothiocyanate, aldehyde, epoxide, anhydride, diimide, and wherein said biopolymer is selected from the group consisting of polyalkylene, Fleximer®, polyethyleneimine (PEI), polylactide/glycolide polymer (PLGA), polyaminoamine (PAMAM), further where said biopolymer is optionally substituted with molecules selected from the group consisting of carbohydrates, proteins, and steroids.
  • said activating group is selected from the group consisting of nitrophenyl, N-hydroxysuccinimide (NHS), isocyanate, isothiocyanate, aldehyde, epoxide, anhydride, diimide
  • said biopolymer is selected
  • the invention includes a method wherein the activated biopolymer is a nitrophenyl activated biopolymer.
  • the invention includes a method wherein the nitrophenyl- activated biopolymer is selected from polyalkylene-nitrophenyl carbonate, Fleximer®- nitrophenyl carbonate, PEI-nitrophenyl, PLGA-nitrophenyl and PAMAM-nitrophenyl.
  • the invention includes a method wherein the first solvent is selected from acetonitrile, DME, dimethylacetamide, dioxane, and tetrahydrofuran.
  • the invention includes a method wherein the buffer solution is selected from bicarbonate buffer, boronate buffer, HCO "3 , CO 2 "2 , B 4 O 7 "2 , PO 4 "2 , TRIS, TRICINE and TAPS.
  • the invention includes a method wherein the second solvent is selected from, DMF, DMSO, NMP and formamide.
  • the first solvent is acetonitrile and the second solvent is DMSO.
  • a method of generating PAGylated nucleic acids allows for efficient modification of amine-modified aptamer nucleic acids.
  • the method includes adding DMSO to avoid PAG side reactions and degradation.
  • the method allows for efficient modification of amine-modified aptamer nucleic acids at a pH at or above 8.5.
  • the method is used to achieve modification of at least 90% of the oligonucleotides in a reaction.
  • the present invention be limited to the use of a polyethylene glycol moiety of a specific molecular weight.
  • the polyethylene glycol moiety comprises a molecular weight greater than 10 kDa.
  • the polyethylene glycol moiety comprises a molecular weight of 20 kDa.
  • the polyethylene glycol moiety comprises a molecular weight of 30 kDa.
  • the polyethylene glycol moiety comprises a molecular weight of 40 kDa.
  • the polyethylene glycol moiety is linear. In one embodiment the polyethylene glycol moiety is branched.
  • the PEG moiety is conjugated to the 5' end of the oligonucleotide. In some embodiments, it is contemplated the PEG moiety will be conjugated to the 3' end of the oligonucleotide.
  • the aptamers of the invention may further comprise a chemical modification selected from the group consisting: of a chemical substitution at a sugar position; a chemical substitution at a phosphate position; and a chemical substitution at a base position of the nucleic acid sequence.
  • the modification is selected from the group consisting of: incorporation of a modified nucleotide; 3 ' capping, and modification of the phosphate back bone.
  • the present invention describes a method for determining the reaction conditions which maximize the conversion of an unPEGylated oligonucleotide to a PEGylated oligonucleotide wherein, in a preferred embodiment, the oligonucleotide is an aptamer.
  • the present invention describes a method for determining the reaction conditions which maximize the conversion of an unPEGylated oligonucleotide to a PEGylated oligonucleotide wherein, in a preferred embodiment, the oligonucleotide is an aptamer.
  • the invention includes a method of attaching a biopolymer to an oligonucleotide containing a terminal amine to form an oligonucleotide-biopolymer derivative.
  • the oligonucleotide-biopolymer comprises formula IA:
  • the method of attaching a biopolymer to an oligonucleotide to form an oligonucleotide-biopolymer derivative comprises: a) dissolving an activated biopolymer in a first solvent to form solution A; b) adding a buffer solution to an aqueous solution comprising the oligonucleotide to form solution B (wherein the pH of solution B is greater than or equal to 8.5); c) combining solution A and solution B to form a reaction mixture; and d) adding a second solvent to the reaction mixture to form a final reaction mixture, wherein the concentration of the oligonucleotide in the aqueous oligonucleotide solution is in a range from about 30 to 70 mg/mL; further wherein the percent of water, including the buffer solution added in step b), in the final reaction mixture is in a range from about 22 to 43%; the percent of the first solvent in the final reaction mixture is in a range from about 7 to 28%; the
  • the activated biopolymer in formula IA is comprised of an activating group and a biopolymer.
  • the activating group is selected from nitrophenyl, N-hydroxysuccinimide (NHS), isocyanate, isothiocyanate, aldehyde, epoxide, anhydride, and diimide.
  • the biopolymer is selected from polyalkylene, Fleximer®, polyethyleneimine (PEI), polylactide/glycolide polymer (PLGA) and polyaminoamine (PAMAM).
  • the biopolymer is optionally substituted with molecules such as carbohydrates (e.g., galactose), proteins (e.g., albumin), steroids (e.g., cholesterol), etc.
  • the activated biopolymer in formula IA is a nitrophenyl activated biopolymer.
  • the nitrophenyl-activated biopolymer is selected from polyalkylene-nitrophenyl carbonate, Fleximer®-nitrophenyl carbonate, PEI- nitrophenyl, PLGA-nitrophenyl, and PAMAM-nitrophenyl.
  • the nitrophenyl-activated biopolymer is mPEG-polyalkylene-nitrophenyl carbonate.
  • the mPEG-polyalkylene-nitrophenyl carbonate has a molecular weight selected from 2000, 5000, 10000, 20000 and 30000.
  • the first solvent in the method for attaching a biopolymer to an oligonucleotide as shown in formula IA is selected from acetonitrile, DME, dimethylacetamide, dioxane and tetrahydrofuran.
  • the buffer solution is selected from bicarbonate buffer, boronate buffer, HCO "3 , CO 2 "2 , B 4 O 7 "2 , PO 4 "2 , TRIS, TRICINE and TAPS (N-tris-(hydroxymethyl)methyl-2-aminopropane sulfonic acid).
  • the second solvent is selected from DMSO, DMF, NMP and formamide.
  • the "concentration of the oligonucleotide” means the concentration of the full length product ("FLP") oligonucleotide in the aqueous oligonucleotide solution e.g., in step d.
  • FLP full length product
  • the concentration of the oligonucleotide is about 30 mg/mL.
  • the concentration of the oligonucleotide is about 50 mg/mL.
  • the concentration of the oligonucleotide is about 70 mg/mL.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is in a range from about 62 to 70% when the concentration of oligonucleotide is about 30 mg/mL.
  • the percent of the oligonucleotide converted to an oligonucleotide- biopolymer derivative is about 62% when the concentration of the oligonucleotide is 30 mg/mL; the percent of the first solvent is about 13.5%; the percent of the second solvent is about 43.3%; and the percent of water is about 43.3%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is about 67% when the concentration of the oligonucleotide is 30 mg/mL; the percent of the first solvent is about 10.7%; the percent of the second solvent is about 55.0%; and the percent of water is about 34.3%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is about 70% when the concentration of the oligonucleotide is 30 mg/mL; the percent of the first solvent is about 8.9%; the percent of the second solvent is about 62.6%; and the percent of water is about 28.5%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is about 64% when the concentration of the oligonucleotide is 30 mg/mL; the percent of the first solvent is about 7.7%; the percent of the second solvent is about 68.0%; and the percent of water is about 24.3%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is in a range from about 65 to 90% when the concentration of oligonucleotide is about 50 mg/mL.
  • the percent of the oligonucleotide converted to an oligonucleotide- biopolymer derivative is about 65% when the concentration of the oligonucleotide is 50 mg/niL; the percent of the first solvent is about 20.0%; the percent of the second solvent is about 40.0%; and the percent of water is about 40.0%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is about 86% when the concentration of the oligonucleotide is 50 mg/mL; the percent of the first solvent is about 16.7%; the percent of the second solvent is about 51.3%; and the percent of water is about 32.0%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is about 95% when the concentration of the oligonucleotide is 50 mg/mL; the percent of the first solvent is about 14.0%; the percent of the second solvent is about 59.1%; and the percent of water is about 26.9%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is about 88% when the concentration of the oligonucleotide is 50 mg/mL; the percent of the first solvent is about 12.0%; the percent of the second solvent is about 64.8%; and the percent of water is about 23.2%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is in a range from about 90 to 99% when the concentration of oligonucleotide is about 70 mg/mL.
  • the percent of the oligonucleotide converted to an oligonucleotide- biopolymer derivative is about 90% when the concentration of the oligonucleotide is 70 mg/mL; the percent of the first solvent is about 27.6%; the percent of the second solvent is about 36.7%; and the percent of water is about 36.7%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is about 94% when the concentration of the oligonucleotide is 70 mg/mL; the percent of the first solvent is about 22.0%; the percent of the second solvent is about 48.0%; and the percent of water is about 30.0%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is about 99% when the concentration of the oligonucleotide is 70 mg/mL; the percent of the first solvent is about 18.5%; the percent of the second solvent is about 56.0%; and the percent of water is about 25.5%.
  • the percent of the oligonucleotide converted to an oligonucleotide-biopolymer derivative is about 91% when the concentration of the oligonucleotide is 70 mg/mL; the percent of the first solvent is about 16.2%; the percent of the second solvent is about 61.8%; and the percent of water is about 22.0%.
  • the pH of solution B in reference to methods for PEGylation using formula I and formula IA the pH of solution B is in a range from about 8.5 to 9.5. In another embodiment, the pH of solution B is about 8.5. In one embodiment, the pH of solution B is 8.5.
  • the concentration of the activated biopolymer in reference to methods for PEGylation using formula I and formula IA is in a range from about 175-225 mg/mL. In one embodiment, in reference to methods for PEGylation using formula I and formula IA the concentration of the nitrophenyl-activated biopolymer in the first solvent is in a range from about 175-225 mg/mL. In another embodiment, in reference to methods for PEGylation using formula I and formula IA the concentration of the nitrophenyl-activated biopolymer in the first solvent is about 200 mg/mL.
  • solution A and solution B are combined by adding solution A to solution B.
  • the volume of the DMSO is greater than the volume of solution A.
  • the volume of the DMSO solvent is twice the volume of solution A.
  • the final reaction mixture in reference to methods for PEGylation using formula I and formula IA the final reaction mixture is stirred for greater than 12 hours. In another embodiment, in reference to methods for PEGylation using formula I and formula IA the final reaction mixture is stirred for between 12-24 hours. In one embodiment, in reference to methods for PEGylation using formula I and formula IA the final reaction mixture is stirred for about 12 hours. In one embodiment, in reference to methods for PEGylation using formula I and formula IA the final reaction mixture is stirred at room temperature.
  • the oligonucleotide is an aptamer.
  • the aptamer comprises about 30-45 nucleotides. In one embodiment, the aptamer comprises about 40 nucleotides. In one embodiment, the aptamer comprises ARC 1635. In one
  • the aptamer is [0055]
  • the oligonucleotide -biopolymer derivative is isolated by HPLC.
  • the oligonucleotide-biopolymer derivative is isolated by gel electrophoresis.
  • the terminal amine of the oligonucleotide is a primary amine. In another embodiment, the terminal amine is a secondary amine.
  • the polyalkylene glycol-oligonucleotide is ARC 1779.
  • the invention includes a method for attaching a polyalkylene glycol group (PAG) to an oligonucleotide containing a terminal amine to form a polyalkylene glycol- oligonucleotide.
  • PAG polyalkylene glycol group
  • the polyalkene glycol-oligonucleotide derivative comprises the formula:
  • the method for attaching a polyalkylene glycol group to form a polyalkylene glycol-oligonucleotide derivative comprises: a) dissolving a nitrophenyl activated biopolymer e.g., PAG-nitrophenylcarbonate in acetonitrile to form solution A; b) adding sodium bicarbonate buffer to an aqueous solution comprising the oligonucleotide to form solution B (wherein the pH of solution B is greater than or equal to 8.5); c) combining solution A and solution B to form a reaction mixture and d) adding DMSO to the reaction mixture to form a final reaction mixture.
  • a nitrophenyl activated biopolymer e.g., PAG-nitrophenylcarbonate in acetonitrile
  • a first portion of DMSO is added to solution A before solution B is added.
  • the amount of DMSO in step d is equivalent to the amount of DMSO in the first portion.
  • 80% acetic acid is added to the final reaction mixture until the pH is within the range of 7.0 to 8.0.
  • nitrophenyl activated biopolymer e.g., PAG-nitrophenylcarbonate is completely dissolved in the acetonitrile.
  • the polyalkylene glycol group is a methoxy polyethylene glycol.
  • nitrophenyl activated biopolymer e.g., PAG-nitrophenylcarbonate is a mPEG- nitrophenylcarbonate.
  • nitrophenyl activated biopolymer e.g., PAG-nitrophenylcarbonate has a molecular weight ranging from 2000-30,000 amu.
  • PAG-nitrophenylcarbonate has a molecular weight selected from 2000, 5000, 10,000, 20,000, and 30,000 amu.
  • PAG-nitrophenylcarbonate has a molecular weight of 20,000 amu.
  • in reference to methods for PEGylation using formula I mPEG-nitrophenylcarbonate has a molecular weight of 20,000 amu.
  • the terminal amine of the oligonucleotide is a primary amine. In another embodiment, in reference to methods for PEGylation using formula I the oligonucleotide is desalted.
  • the pH of solution B ranges from 8.5 to 9.5. In one embodiment, in reference to methods for PEGylation using formula I the pH of solution B is about 8.5. In one embodiment, the pH of solution B is 8.5. In one embodiment, in reference to methods for PEGylation using formula I the pH of the final reaction mixture (i.e., the mixture of the oligo, PEG reagent, and DMSO mixed together) is about 8.5.
  • sodium bicarbonate buffer is added until the sodium bicarbonate concentration of solution B is 100 mM.
  • the concentration of the oligonucleotide in the aqueous oligonucleotide solution is greater than 30 mg/mL.
  • the concentration of the oligonucleotide is between 30-70 mg/mL.
  • the concentration of the oligonucleotide in the is between 40-70 mg/mL.
  • the concentration of said oligonucleotide in said aqueous oligonucleotide solution is selected from 30, 40, 50, and 70 mg/mL.
  • the concentration of nitrophenyl activated biopolymer e.g., PAG-nitrophenylcarbonate in acetonitrile is in a range of about 175-225 mg/mL.
  • the concentration of nitrophenyl activated biopolymer e.g., mPEG-nitrophenylcarbonate in acetonitrile is in a range of about 175-225 mg/mL.
  • the concentration of nitrophenyl activated biopolymer e.g., PAG-nitrophenylcarbonate in acetonitrile is about 200 mg/mL.
  • the concentration of nitrophenyl activated biopolymer e.g., PEG- nitrophenylcarbonate in acetonitrile is about 200 mg/mL.
  • solution A and solution B are combined by adding solution A to solution B.
  • the volume of DMSO added is greater than the volume of solution A.
  • the volume of DMSO added is twice the volume of solution A.
  • the final reaction mixture in reference to methods for PEGylation using formula I is stirred for greater than 12 hours. In one embodiment, in reference to methods for PEGylation using formula I the final reaction mixture is stirred for between 12- 24 hours. In one embodiment, in reference to methods for PEGylation using formula I the final reaction mixture is stirred for about 12 hours. In one embodiment, in reference to methods for PEGylation using formula I the final reaction mixture is stirred at room temperature. In one embodiment, in reference to methods for PEGylation using formula I the oligonucleotide is an aptamer. In one embodiment, in reference to methods for PEGylation using formula I the aptamer comprises about 30-45 nucleotides.
  • the aptamer in reference to methods for PEGylation using formula I the aptamer comprises about 40 nucleotides. In one embodiment, in reference to methods for PEGylation using formula I the aptamer comprises ARC 1779. In one embodiment, in reference to methods for PEGylation
  • the polyalkylene glycol-oligonucleotide derivative in reference to methods for PEGylation using formula I is isolated by liquid chromatography. In one embodiment, in reference to methods for PEGylation using formula I the polyalkylene glycol-oligonucleotide derivative is isolated by HPLC.
  • the percent conversion of oligonucleotide to polyalkylene glycol-oligonucleotide derivative is greater than 60%. In another embodiment, in reference to methods for PEGylation using formula I the percent conversion of oligonucleotide to polyalkylene glycol-oligonucleotide derivative is in a range between 62-99%.
  • the percentage of water in the final reaction mixture is less than 45% of the total volume of the final reaction mixture. In another embodiment, in reference to methods for PEGylation using formula I the percentage of water in the final reaction mixture is in a range between 22-43% of the total volume of the final reaction mixture.
  • the percentage of DMSO in the final reaction mixture is less than 70% of the total volume of the final reaction mixture. In another embodiment, in reference to methods for PEGylation using formula I the percentage of DMSO in the final reaction mixture is in a range between 36-68% of the total volume of the final reaction mixture. In another embodiment, in reference to methods for PEGylation using formula I the percentage of acetonitrile in the final reaction mixture is less than 30% of the total volume of the final reaction mixture. In another embodiment, in reference to methods for PEGylation using formula I the percentage of acetonitrile in the final reaction mixture is in a range between 7-28% of the total volume of the final reaction mixture. In one embodiment, in reference to methods for PEGylation using formula I the polyalkylene glycol-oligonucleotide is isolated.
  • the polyalkylene glycol-oligonucleotide is ARC 1779.
  • the invention includes a method for optimizing the yield of 1 :1 polyalkylene glycol-oligonucleotide in an aqueous solution comprising: a) dissolving PAG-nitrophenylcarbonate in acetonitrile to form solution A; b) adding sodium bicarbonate buffer to an aqueous solution comprising the oligonucleotide to form solution B (wherein the pH of solution B is greater than or equal to 8.5); c) combining solution A and solution B to form a reaction mixture and d) adding DMSO to the reaction mixture to form a final reaction mixture.
  • a first portion of DMSO is added to solution A before solution B is added.
  • the amount of DMSO in step d) is equivalent to the amount of DMSO in the first portion.
  • 80% acetic acid is added to the final reaction mixture until the pH is within the range of 7.0-8.0.
  • a preferred solvent ratio of water to DMSO to acetonitrile is about: 2:4:1.
  • the invention includes a method of preparing ARC 1779 as show in Scheme 2.
  • the invention includes a method of reacting a compound
  • ARC form ARC 1779 wherein the method comprises: a) dissolving in acetonitrile to form solution A; b) adding sodium bicarbonate buffer to an aqueous solution of
  • ARC136E to form solution B (wherein the pH of solution B is greater than or equal to 8.5); c) combining solution A and solution B to form the reaction mixture and d) adding DMSO to the reaction mixture to form the final reaction mixture.
  • the invention includes a method of synthesis of ARC 1779 on controlled pore glass (CPG) with an optimized activator-to-amidite ratio, amidite equivalents, and amidite contact time; an on-column base wash optimized to eliminate CE group; deprotection in using ammonia vs. methylamine vs. mixture; and ion exchange (IEX) purification. In one embodiment, purification up to about 80% purity. Definitions
  • “Oligonucleotide” means a molecule comprising a nucleic acid of 30-65 nucleotides.
  • the nucleic acid can be DNA or RNA.
  • the nucleic acid is the "all phosphate version” or "all PO.”
  • the term "all phosphate containing version” or “all PO” refers to an oligonucleotide wherein the linker group between the sugar molecules of the nucleic acid portion is a phosphate group.
  • the oligonucleotide may contain an amino (amine) group and optionally a linker.
  • the nucleic acid portion of the oligonucleotide is attached to the amino group through a linker e.g.
  • amino group is a primary or secondary amine. In one aspect, the amino group is a terminal amine. In one aspect, the amino group is -NH 2 , a primary amine.
  • the oligonucleotide is, e.g., an aptamer, an aptamer that comprises ARC1368.
  • I — — 1 refers to the nucleic acid portion of the oligonucleotide attached to a linker group.
  • the linker group can include a phosphate moiety as shown in Structure 1.
  • ARC 1779 refers to the aptamer shown in Structure 1 having the sequence (reading from the 5' end to the 3' end): mPEG20K-NH-C 6 Hi2-OP(O 2 )O-mG-mC-mG-mU-dG-dC-dA-mG-mU-mG-mC-mC-mC- mU-mU-mC-mG-mG-mC-dC-mG-s-dT-mG-dC-dG-dG-dT-mG-mC-dC-mU-dC-dC- mG-mU-dC-mA-mC-mG-mC-idT (SEQ ID NO. 1)
  • ARC 1635 refers to the aptamer having the sequence (reading from the 5' end to the 3' end):
  • ARC 1368 refers to the aptamer having the sequence (reading from the 5' end to the 3' end): mG-mC-mG-mU-dG-dC-dA-mG-mU-mG-mC-mC-mU-mU-mC-mG-mG-mC-dC- mG-s-dT-mG-dC-dG-dG-dT-niG-mC-dC-mU-dC-dC-mG-mU-dC-mA-mC-mG-mC- idT (SEQ ID NO. 3)
  • PEGylation refers to the attachment of one or more polyethylene glycol (PEG) substituents or derivatives thereof to another molecule (e.g., an aptamer).
  • PEG polyethylene glycol
  • Polyalkylene glycol groups or “PAGs” are polymers which typically have the properties of solubility in water and in many organic solvents, lack of toxicity, and lack of immunogenicity.
  • PAGs are polymers which typically have the properties of solubility in water and in many organic solvents, lack of toxicity, and lack of immunogenicity.
  • One use of PAGs is to covalently attach the polymer to insoluble molecules to make the resulting PAG-molecule "conjugate" soluble.
  • the water-insoluble drug paclitaxel when coupled to PEG, becomes water-soluble. Greenwald, et ah, J. Org. Chem., 60:331-336 (1995).
  • PAG conjugates are often used not only to enhance solubility and stability but also to prolong the blood circulation half-life of molecules.
  • Such PAG polymers can be linear or branched.
  • Typical PAG polymers used in the invention include poly(ethylene glycol) (PEG), also known as or poly(ethylene oxide) (PEO) and polypropylene glycol (including poly isopropylene glycol). Additionally, random or block copolymers of different alkylene oxides (e.g., ethylene oxide and propylene oxide) can be used in many applications.
  • PEG poly(ethylene glycol)
  • PEO poly(ethylene oxide)
  • Ppropylene glycol including poly isopropylene glycol
  • random or block copolymers of different alkylene oxides e.g., ethylene oxide and propylene oxide
  • a polyalkylene glycol, such as PEG is a linear polymer terminated at each end with hydroxyl groups: HO-CH 2 CH 2 O-(CH 2 CH 2 O) n -CH 2 CH 2 -OH, where n ranges from about 4 to 10,000.
  • the PEG molecule is di-functional and is sometimes referred to as "PEG diol.”
  • the terminal portions of the PEG molecule are relatively non-reactive hydroxyl moieties, the -OH groups, that can be activated, or converted to functional moieties, for attachment of the PEG to other compounds at reactive sites on the compound.
  • Such activated PEG diols are referred to herein as bi-activated PEGs.
  • the terminal moieties of PEG diol have been functionalized as active carbonate ester for selective reaction with amino moieties by substitution of the relatively nonreactive hydroxyl moieties, -OH, with succinimidyl active ester moieties from N-hydroxysuccinimide.
  • PAG molecule on one end it is desirable to cap the PAG molecule on one end with an essentially non-reactive moiety so that the PAG molecule is mono-functional (or mono- activated).
  • PAG molecule In the case of protein therapeutics which generally display multiple reaction sites for activated PAGs, bi-functional activated PAGs lead to extensive cross-linking, yielding poorly functional aggregates.
  • mono-activated PAGs one hydroxyl moiety on the terminus of the PAG diol molecule typically is substituted with non-reactive methoxy end moiety, -OCH 3 .
  • the other, un-capped terminus of the PAG molecule typically is converted to a reactive end moiety that can be activated for attachment at a reactive site on a surface or a molecule such as a protein.
  • mPEG methoxy polyethylene glycol or CH 3 O(CH 2 CH 2 O) n OH, where n ranges from about 4 to about 10,000.
  • activated PAG means a compound having a PAG group linked to an activating group, wherein the activated PAG compound contains an activated carbonyl or equivalent which promotes conjugation of the oligonucleotide to the PAG.
  • activating groups include nitrophenyl, N-hydroxysuccinimide(NHS), isocyanate, isothiocyanate, aldehyde, epoxide anhydride, and diimide.
  • Examples of an activated PAG include PAG-nitrophenylcarbonate or PAG-N-hydroxysuccinimide.
  • the activating group is linked to the PAG through a bond, a carbonyl, a carbamate, or a methylene group(s), etc.
  • PAG-nitrophenylcarbonate means a polyalkylene p-nitrophenyl carbonate
  • terminal amine e.g., primary amine.
  • the amine can be a hexamethyl amine linker.
  • idT means an inverted deoxythymidine.
  • the term "desalted” or “desalting” refers to the removal of salt or small molecules from a macromolecule. This is achieved, for example, by gel filtration, TFF (tangential flow filtration), or UF/DF (ultrafiltration/diafiltration).
  • Biopolymer means polyalkylene, Fleximer®, polyethyleneimine (PEI), polylactide/glycolide polymer (PLGA), polyaminoamine (PAMAM), further where said biopolymer is optionally substituted with molecules selected from the group consisting of carbohydrates, proteins, and steroids.
  • activated biopolymer means a compound having a biopolymer group linked to an activating group, wherein the activated biopolymer compound contains an activated carbonyl or equivalent which promotes conjugation of the oligonucleotide to the biopolymer.
  • the activating group is selected from nitrophenyl, N- hydroxysuccinimide (NHS), isocyanate, isothiocyanate, aldehyde, epoxide anhydride, and diimide.
  • an activated biopolymers include mPEG-nitrophenylcarbonate or mPEG-N-hydroxysuccinimide.
  • the activating group is linked to the biopolymer through a bond, a carbonyl, a carbamate, or a methylene group(s), etc.
  • DMSO dimethylsulfoxide
  • PAG polyalkylene glycol
  • PEG polyethylene glycol
  • mPEG methoxy polyethylene glycol or CH 3 O(CH 2 CH 2 O) n OH.
  • mPEG attached to another atom is depicted as CHsO(CH 2 CH 2 O) n CH 2 CH 2 -, where n is not 0 or 1;
  • NPC nitrophenylcarbonate
  • PEI polyethyleneimine
  • PLGA polylactide/glycolide
  • PAMAM polyaminoamine
  • TAPS N-tris(hydroxymethyl)methyl-2-aminopropane sulfonic acid
  • HPLC high performance liquid chromatography
  • NLT not longer than
  • kDa, K used interchangeably throughout: kilo Dalton.
  • oligonucleotides with high molecular weight non-immunogenic polymers has the potential to alter the pharmacokinetic and pharmacodynamic properties of nucleic acids making them more effective therapeutic agents.
  • Favorable changes in activity can include increased resistance to degradation by nucleases, decreased filtration through the kidneys, decreased exposure to the immune system, and altered distribution of the therapeutic through the body.
  • the aptamer compositions of the invention may be derivatized with polyalkylene glycol ("PAG”) moieties.
  • PAG polyalkylene glycol
  • PAG-derivatized nucleic acids are found in United States Patent Application Publication No. US2004-0180360, filed on November 21, 2003, which is herein incorporated by reference in its entirety.
  • Typical polymers used in the invention include poly(ethylene glycol) (“PEG”), also known as poly(ethylene oxide) (“PEO”) and polypropylene glycol (including poly isopropylene glycol). Additionally, random or block copolymers of different alkylene oxides (e.g., ethylene oxide and propylene oxide) can be used in many applications.
  • a polyalkylene glycol such as PEG
  • PEG is a linear polymer terminated at each end with hydroxyl groups: HO- CH 2 CH 2 O-(CH 2 CH 2 O) n -CH 2 CH 2 -OH.
  • This polymer, alpha-, omega- dihydroxylpoly(ethylene glycol), can also be represented as HO-PEG-OH, where it is understood that the -PEG- symbol represents the following structural unit: -CH 2 CH 2 O- (CH 2 CH 2 O) n -CH 2 CH 2 -, where n typically ranges from about 4 to about 10,000.
  • PAG polymers suitable for therapeutic indications typically have the properties of solubility in water and in many organic solvents, lack of toxicity, and lack of immunogenicity.
  • One use of PAGs is to covalently attach the polymer to insoluble molecules to make the resulting PAG-molecule "conjugate" soluble.
  • the water-insoluble drug paclitaxel when coupled to PEG, becomes water-soluble. Greenwald, et ah, J. Org. Chem., 60:331-336 (1995).
  • PAG conjugates are often used not only to enhance solubility and stability but also to prolong the blood circulation half-life of molecules.
  • PAG derivatization e.g., PEG conjugation
  • the ability of PAG derivatization, e.g., PEG conjugation, to alter the biodistribution of a therapeutic is related to a number of factors including the apparent size (e.g., as measured in terms of hydrodynamic radius) of the conjugate. Larger conjugates (>10 kDa) are known to more effectively block filtration via the kidney and to consequently increase the serum half- life of small macromolecules (e.g., peptides, antisense oligonucleotides).
  • small macromolecules e.g., peptides, antisense oligonucleotides.
  • the ability of PEG conjugates to block filtration has been shown to increase with PEG size up to approximately 50 kDa (further increases have minimal beneficial effect as half life becomes defined by macrophage-mediated metabolism rather than elimination via the kidneys).
  • the PAG derivatized compounds of the invention are typically between 5 and 80 kDa in size however any size can be used, the choice dependent on the aptamer and application.
  • Other PAG derivatized compounds of the invention are between 10 and 80 kDa in size.
  • Still other PAG derivatized compounds of the invention are between 10 and 60 kDa in size.
  • the PAG moieties derivatized to compositions of the present invention are PEG ranging from 10, 20, 30, 40, 50, 60, or 80 kDa in size.
  • the PEG is linear PEG, while in other embodiments, the PEG is branched PEG.
  • the PEG is a 40 kDa branched PEG.
  • the 40 kDa branched PEG is attached to the 5' end of the aptamer.
  • the present invention provides a cost effective route to the synthesis of PEG- nucleic acid (e.g., an aptamer) conjugates including multiply PEGylated nucleic acids.
  • the present invention also encompasses PEG-linked multimeric oligonucleotides, e.g., dimerized aptamers.
  • nucleic acid therapeutics are typically chemically synthesized from activated monomer nucleotides.
  • PEG-nucleic acid conjugates may be prepared by incorporating the PEG using the same iterative monomer synthesis. For example, PEGs activated by conversion to a para-nitrophenylcarbonate form can be incorporated into solid-phase oligonucleotide synthesis.
  • terminal portions of these higher molecular weight PEG molecules i.e., the relatively non-reactive hydroxyl (-OH) moieties
  • Branched activated PEGs will have more than two termini, and in cases where two or more termini have been activated, such activated higher molecular weight PEG molecules are herein referred to as, multi- activated PEGs. In some cases, not all termini in a branch PEG molecule are activated. In cases where any two termini of a branch PEG molecule are activated, such PEG molecules are referred to as bi-activated PEGs.
  • PEG molecules are referred to as mono-activated.
  • activated PEG prepared by the attachment of two monomethoxy PEGs to a lysine core which is subsequently activated for reaction has been described (Harris et al., Nature, vol. 2: 214-221, 2003).
  • the linear PEG molecule is di-functional and sometimes referred to as "PEG diol.”
  • the terminal portions of the PEG molecule are relatively non-reactive hydroxyl moieties, the -OH groups, that can be activated, or converted to functional moieties, for attachment of the PEG to other compounds at reactive sites on the compound.
  • Such activated PEG diols are referred to herein as bi-activated PEGs.
  • the terminal moieties of PEG diol have been functionalized as active carbonate ester for selective reaction with amino moieties by substitution of the relatively non-reactive hydroxyl moieties, -OH, with succinimidyl active ester moieties from N-hydroxy succinimide.
  • the PEG diols can be activated with a variety of groups, including without limitation ⁇ -halo acetic acids, epihalohydrines, maleates, tartrates and carbohydrates which after appropriate manipulation would yield an activated carbonyl or equivalent for conjugation.
  • groups including without limitation ⁇ -halo acetic acids, epihalohydrines, maleates, tartrates and carbohydrates which after appropriate manipulation would yield an activated carbonyl or equivalent for conjugation.
  • Other methods of activating PEG are described in Roberts et al., (2002) Advanced Drug Deliver Reviews 54:549-476, herein incorporated by reference in its entirety.
  • one or both of the terminal alcohol functionalities of the PEG molecule can be modified to allow for different types of conjugation to a nucleic acid.
  • converting one of the terminal alcohol functionalities to an amine, or a thiol allows access to urea and thiourethane conjugates.
  • bi-functional activated PEGs lead to extensive cross-linking, yielding poorly functional aggregates.
  • one hydroxyl moiety on the terminus of the PEG diol molecule typically is substituted with non-reactive methoxy end moiety, -OCH3.
  • the other, un-capped terminus of the PEG molecule typically is converted to a reactive end moiety that can be activated for attachment at a reactive site on a surface or a molecule such as a protein.
  • high molecular weight PAG-nucleic acid-PAG conjugates can be prepared by reaction of a mono-functional activated PEG with a nucleic acid containing more than one reactive site.
  • the nucleic acid is bi-reactive, and contains two reactive sites: a 5 '-amino group and a 3'- amino group introduced into the oligonucleotide through conventional phosphoramidite synthesis and starting with a 3 '-amine solid support, for example: 3'-5'-di-PEGylation.
  • reactive sites can be introduced at internal positions, using for example, the 5-position of pyrimidines, the 8-position of purines, or the 2 '-position of ribose as sites for attachment of primary amines.
  • the nucleic acid can have several activated or reactive sites and is said to be multiply activated.
  • the present invention also contemplates high molecular weight aptamer compositions in which two or more nucleic acid moieties are covalently conjugated to at least one polyalkylene glycol moiety, thereby, producing a nucleic acid- PAG-nucleic acid conjugate.
  • the polyalkylene glycol moieties serve as stabilizing moieties.
  • a stabilizing moiety is a molecule, or portion of a molecule, which improves pharmacokinetic and pharmacodynamic properties of the high molecular weight aptamer compositions of the invention.
  • a stabilizing moiety is a molecule or portion of a molecule which brings two or more aptamers, or aptamer domains, into proximity, or provides decreased overall rotational freedom of the high molecular weight aptamer compositions of the invention.
  • a stabilizing moiety can be a polyalkylene glycol, such a polyethylene glycol, which can be linear or branched, a homopolymer or a heteropolymer.
  • Other stabilizing moieties include polymers such as peptide nucleic acids (PNA).
  • Oligonucleotides can also be stabilizing moieties; such oligonucleotides can include modified nucleotides, and/or modified linkages, such as phosphorothioates.
  • linker sequence can be influenced by both its chemical composition and length.
  • a linker that is too short will clearly preclude the formation of a chelate.
  • a linker that forms unfavorable steric and/or ionic interactions with the target will also negate the stabilizing effects of chelation.
  • lengthening of the linker, beyond that necessary to span the distance between binding sites may reduce binding stability by diminishing the effective concentration of the ligand.
  • the methods of the present invention be limited to any specific linker and/or biopolymer (as illustrated by the synthetic scheme set out in Figure 7).
  • the methods of the invention describe a means for determining the most efficient protocol for the PEGylation of a given oligonucleotide. By systematically varying the concentration and reaction conditions for reagents in a given PEGylation protocol, the conditions which will maximize the yield of PEGylated product for a given amount of oligonucleotide and a given equivalent of a biopolymer (in a preferred embodiment mPEG) may be elucidated through a small number of test reactions (e.g. in a range of six to twelve reactions as demonstrated in Example 1).
  • the present invention demonstrates that a PEGylation protocol validated as most efficient using mg amounts of oligonucleotide and biopolymer directly scale for large lot production of given PEGylated oligonucleotide (e.g. the optimal reagent ratios for the PEGylation of ARC1368-(CH 2 ) 6 NH 2 to ARC1779 described in the instant application have been used in the kilogram production of ARC 1779.
  • a PEGylation protocol validated as most efficient using mg amounts of oligonucleotide and biopolymer directly scale for large lot production of given PEGylated oligonucleotide (e.g. the optimal reagent ratios for the PEGylation of ARC1368-(CH 2 ) 6 NH 2 to ARC1779 described in the instant application have been used in the kilogram production of ARC 1779.
  • the methods of the present invention be limited to determining the optimal conditions for the PEGylation of an oligonucleotide. It is also contemplated that the methods of the present invention could be adapted to optimize the conditions for the PEGylation of a peptide or protein. Indeed, many methods are available for linking mPEG to proteins, usually to their amino groups of lysine residues or N-terminal of the polypeptide sequence (Zalipsky, Bioconjugate Chem., 6:150-165, 1995; Zalipsky, Adv.
  • PEG reagents that are used to make urethane linked PEG-proteins (Zalipsky, supra; Veronese et al., 1985, Appl. Biochem. Biotechnol., 11 :141-152). These include slow-reacting imidazolyl formate, trichlorophenyl carbonate, and nitrophenyl carbonate (NPC) derivatives. See, US Patent Application Publication Number US 20060286657 Al, listing Zalipsky as inventor.
  • PEGylation of oligonucleotides was accomplished with a para-nitrophenol activated PEG moiety (PEG-PNP).
  • PEG-PNP para-nitrophenol activated PEG moiety
  • This method is applicable to all oligonucleotides containing a primary amine and is useful from the small- (e.g., benchtop reactions) to large- (e.g., GMP) scale.
  • the method was developed using standard chemistry deprotonating the primary amine on the oligonucleotide by raising the reaction pH to 8.5 using a carbonate buffer.
  • the aptamer was provided as aqueous solution, with an ideal concentration between 40 and 70 mg/mL in 100 mM NaHCO 3 pH 8.5.
  • the 20 kDa mPEG p-nitrophenyl carbonate reagent (NOF) was dissolved to a concentration of 200 mg/mL in acetonitrile.
  • Aptamer solution was added to the PEG reagent, and 2 times the equal volume of DMSO was added to the PEGylation reaction. The reaction was then incubated at room temperature overnight and the reaction progress was monitored by HPLC.
  • Table 2 shows that the optimal solvent ratio, at an oligonucleotide concentration of 50 mg/mL, is about 2:4:1, water:DMSO:ACN.
  • Figures 4 and Figure 5 are HPLC traces of reaction mixtures 7 and 11, as shown in Table 1, respectively. Unreacted precursor oligonucleotide was observed at about 8.25 min. Both HPLC traces were generated using Strong Anion eXchange HPLC to monitor the progress of the reaction.
  • Figure 6 is an HPLC trace of the unPEGylated starting material for PEGylation studies, 90%, 40 mg/mL concentration. The HPLC trace was generated using Strong Anion eXchange HPLC to monitor the progress of the reaction.
  • Figure 9 depicts a RP-HPLC trace that shows the specificity of the PEGylation reaction.
  • the upper trace shows the reaction of ARC 1368-(CH 2 )ONH 2 (also referred to herein as ARC 1635) with 2 equivalents of PEG reagent.
  • the lower trace illustrates the reaction of the non-amine bearing ARC1368.
  • both ARC 1368-(CH 2 ) 6 NH 2 and ARC 1368 were subjected to the PEGylation reaction conditions with another full equivalent of PEG reagent as illustrated in Figure 10.
  • ARC1368-(CH 2 ) 6 NH 2 is completely reacted to form ARC 1779, while in the lower trace, the extent of reaction is limited to less than 3%.
  • Figure 11 shows the LCMS study of PEGylation reaction, illustrating that only amine bearing oligonucleotides will PEGylate.
  • Figure 12 shows co-injection of ARC1635 and the all PO version of ARC1635, on strong anion exchange (SAX) HPLC. As shown, SAX-HPLC resolved the ARC 1635 and the all phosphate version of ARC 1635.
  • Figure 13 shows co-injection of ARC 1779 and the all PO containing version, on strong anion exchange (SAX) HPLC. As shown, SAX-HPLC resolved the ARC 1779 and the all phosphate version of ARC 1779.
  • Figure 14 is a reverse-phase HPLC trace showing all ARC 1779 and the all PO version of ARC 1779, on reverse phase (RP)HPLC. As shown, RP-HPLC did not resolve the ARC 1779 and the all phosphate version of ARC 1779.
  • the methods of the present invention also reduce the amount of impurities formed during the conjugation of an oligonucleotide with a PEG moiety.
  • Analysis of the impurities of the chemical reaction show in Scheme 2 showed the following unPEGylated impurities: +69 Da - iBu adduct; +53 Da - CE adduct; and N+ species without amine linker.
  • the following PEGylated impurities were also identified: all phosphodiester, deletion failures with amine; N+ products with amine; and other adducts.
  • the impurity is unreacted oligonucleotide.
  • the method was developed as part of the process development of ARC1779, in order to facilitate large scale GMP manufacturing of ARC 1779.
  • ARC1368 was incubated with 2 equivalents of nitrophenol under PEGylation reaction conditions.
  • the stability of the aptamer core was monitored over a 36 hour period at 35 0 C at 3, 12, and 36 hours.
  • the results of this study are shown in Figure 8. As illustrated, the core aptamers itself was unchanged under the extended reaction conditions.
  • 5'-amine functions are attached with an amino-modifier C6 reagent, and the 3'-amine is introduced using 3 '-amino-modifier C3 CPG (e.g., Glen Research, Sterling, VA).
  • C3 CPG e.g., Glen Research, Sterling, VA.
  • the oligonucleotides are evaporated to dryness, ethanol precipitated twice to remove residual ammonia, and re-dissolved in water to a concentration of 1 mM.
  • oligonucleotide 7.5 ⁇ L of the oligonucleotide are mixed with an equal volume of 200 mM NaHCO 3 -buffer pH 8.5, and 15 ⁇ L of mPEG-SPA 20 kDa (mPEG- succinimidyl propionate) at a concentration of 40 mg/mL or mPEG-NHS 40 kDa at a concentration of 80 mg/mL in acetonitrile
  • mPEG-SPA 20 kDa mPEG- succinimidyl propionate
  • RP-HPLC analysis was performed on a DNA-Prep HC column (Transgenomic, Omaha, NE), solvent A 100 mM TEAA, solvent B 100 mM TEAA in 90% v/v acetonitrile, 5-100% B in 18 min, column temperature 80 0 C, injection 10 ⁇ L, absorbance detection at 260 nm.
  • the purification HPLC traces are shown in Figure 3, and indicate the successful preparation of di-PEGylated conjugates with molecular weights up to 80 kDa PEG.
  • Step 1 The reaction was performed in a 10 L size prep, container and labeled.
  • Step 2 Add 1.4 kg of 20 kDa PNP-activated PEG to the prep, container.
  • Step 3 Add 7 L acetonitrile to the prep, container.
  • Step 4. Mix solution until the 20 kDa PNP-activated PEG is completely in solution.
  • Step 5. Transfer the dissolved PEG in acetonitrile from the prep, container to the vented reaction tank.
  • Step 6 Add 13 L of DMSO to rinse residual PEG solution into reaction container.
  • Step 7 Transfer DMSO to reaction tank.
  • Step 8 Prior to transfer of the buffered oligo, agitate contents of the reaction tank.
  • Step 9 Transfer the 450 g of oligonucleotide in 12.5 L of water to the vented reaction tank. Transfer of the oligo is done over a time period of no less than 30 min. due to an exothermic potential.
  • Step 10 Add the remaining 13 L of DMSO to rinse the residual oligonucleotide solution into the reaction container.
  • Step 11 When the transfer of DMSO is complete, remove pump assembly connections, and record the start time and date for the conjugation reaction. Reaction time required is 20 hr +/-4 hr. Continue mixing for entire reaction time period.
  • Step 12 The progress of the chemical reaction is monitored by removing and analyzing 2 mL aliquots at 1, 3, and 16 hour time-points from the start of the conjugation reaction using analytical Strong Anion eXchange HPLC, cf. 00146.
  • Step 13 Transfer 180 g OfNaH 2 PO 4 solution to the vented reaction tank. Transfer of the solution must be over a time period of NLT 30 min. due to potential off-gassing.
  • Step 14 When transfer is complete, the contents are allowed to mix for NLT 5 min.
  • Step 15 The pH of the reaction mixture is measured at room temperature by removing a 5 mL aliquot of the reaction mixture into 50 mL conical tube and QS up to ⁇ 25 mL with water.
  • Step 16 If pH is above 8.5, the pH of the reaction mixture is further adjusted with 80% acetic acid until the pH is within the range of 7.0-8.0. NLT 2 min of mixing is allowed to occur between samplings. [00166] Step 17. When pH range is reached, the reaction mixture is allowed to mix for NLT 5 min prior to transfer from reaction tank to IOOL carboy.
  • Step 18 Transfer the reaction mixture to a 100 L carboy for ultrafiltration (UF) processing.

Abstract

Méthode de conjugaison d'un biopolymère, tel qu'un polyalkylène glycol (PAG) et d'un oligonucléotide consistant à combiner une biopolymère activé et un oligonucléotide dans une solution aqueuse à pH de 8.5 ou plus et à ajouter un DMSO afin d'éviter des réactions latérales et une dégradation du PEG.
PCT/US2008/085594 2007-12-04 2008-12-04 Conjugaison biopolymère-acide nucléique WO2009073820A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US538207P 2007-12-04 2007-12-04
US61/005,382 2007-12-04

Publications (2)

Publication Number Publication Date
WO2009073820A2 true WO2009073820A2 (fr) 2009-06-11
WO2009073820A3 WO2009073820A3 (fr) 2009-09-24

Family

ID=40718503

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2008/085596 WO2009073821A2 (fr) 2007-12-04 2008-12-04 Conjugaison biopolymère-acide nucléique
PCT/US2008/085594 WO2009073820A2 (fr) 2007-12-04 2008-12-04 Conjugaison biopolymère-acide nucléique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2008/085596 WO2009073821A2 (fr) 2007-12-04 2008-12-04 Conjugaison biopolymère-acide nucléique

Country Status (1)

Country Link
WO (2) WO2009073821A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105839A1 (en) * 2001-11-28 2004-06-03 Myung-Ok Park Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629456B2 (en) * 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
PL3385384T3 (pl) * 2004-02-12 2021-03-08 Archemix Llc Aptamerowe środki terapeutyczne użyteczne w leczeniu zaburzeń powiązanych z dopełniaczem

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105839A1 (en) * 2001-11-28 2004-06-03 Myung-Ok Park Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARAN ET AL.: 'A Versatile Photocleavable Bifunctional Linker for Facile Synthesis of Substrate- DNA Conjugates for the Selection of Nucleic Acid Catalysts' BIOCONJUGAT. CHEM., [Online] 2007, Retrieved from the Internet: <URL:http://mmi.missouri.edu/burke/Saran_Ph otocleavable BioconjChem2007.pdf> [retrieved on 2009-07-22] *

Also Published As

Publication number Publication date
WO2009073820A3 (fr) 2009-09-24
WO2009073821A3 (fr) 2009-08-27
WO2009073821A2 (fr) 2009-06-11

Similar Documents

Publication Publication Date Title
US8987377B2 (en) Poly(amide) polymers for the delivery of oligonucleotides
US9402914B2 (en) Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides
US20070009476A1 (en) Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
WO2007084797A1 (fr) POLYMÈRE À POLYCATION CHIMIQUEMENT MODIFIÉ POUR ADMINISTRATION D&#39;ARNsi
JPWO2006088248A1 (ja) ポリオキシアルキレン誘導体
EP2576655A2 (fr) Synthèse de polymères activée par membrane
WO2013162041A1 (fr) Composition pharmaceutique de type structure unitaire pour une administration d&#39;acide nucléique
Choi et al. Effect of poly (ethylene glycol) grafting on polyethylenimine as a gene transfer vector in vitro
JP2010503705A (ja) ヒンダードエステル系の生分解性リンカーを有するポリアルキレンオキサイド
JPWO2005078084A1 (ja) ２本鎖オリゴ核酸を担持したポリイオンコンプレックスおよびその製造法とそれを含む医薬組成物
US20120277419A1 (en) Method for manufacturing pegylated oligonucleotides
WO2009073820A2 (fr) Conjugaison biopolymère-acide nucléique
JP2020076111A (ja) 優れたペプチドおよびタンパク質結合特性を備えたグラフトコポリマー賦形剤の生成の方法
WO2008048079A1 (fr) Formulation biopharmaceutique à action de longue durée
WO2013062982A1 (fr) Homopolymères poly(lysine) pour l&#39;administration d&#39;oligonucléotides
US8247493B2 (en) Long acting formulation of biopharmaceutical
WO2003093346A1 (fr) Derives de polyethyleneglycol multifonctionnels, leur preparation et utilisation
KR102611562B1 (ko) 과량의 폴리알콕시화 시약의 회수 및 재순환을 위한 핵산의 폴리알콕시화 방법
JP7281140B2 (ja) 生体関連物質とブロックポリマーとの結合体、および前記結合体を得るためのブロックポリマー誘導体
Wang et al. New method for the preparation of adsorbent with high adsorption capacity
WO2013016057A1 (fr) Homopolymères de poly(ornithine) pour l&#39;administration d&#39;oligonucléotides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856840

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08856840

Country of ref document: EP

Kind code of ref document: A2